These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23593719)

  • 1. US FDA approves three new drugs for Type 2 diabetes.
    Bond T
    Expert Rev Clin Pharmacol; 2013 Mar; 6(2):101. PubMed ID: 23593719
    [No Abstract]   [Full Text] [Related]  

  • 2. New drugs improve glycemic control in type 2 diabetes, but improving heart health remains elusive.
    Mitka M
    JAMA; 2013 Oct; 310(14):1435-6. PubMed ID: 24104360
    [No Abstract]   [Full Text] [Related]  

  • 3. Alogliptin (nesina) for type 2 diabetes.
    Med Lett Drugs Ther; 2013 May; 55(1417):41-3. PubMed ID: 23715128
    [No Abstract]   [Full Text] [Related]  

  • 4. [Not Available].
    Van Genechten D; Duh D
    J Pharm Belg; 2015 Dec; (4):33-5. PubMed ID: 26856110
    [No Abstract]   [Full Text] [Related]  

  • 5. Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes.
    Deacon CF
    Curr Opin Investig Drugs; 2008 Apr; 9(4):402-13. PubMed ID: 18393107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticipated US approval for rosiglitazone and pioglitazone.
    Diabetes Obes Metab; 1999 May; 1(3):181-2. PubMed ID: 11220298
    [No Abstract]   [Full Text] [Related]  

  • 7. DPP-4 inhibitors and risk of heart failure EXAMINEd.
    Standl E; Schnell O
    Lancet; 2015 May; 385(9982):2022-4. PubMed ID: 25765695
    [No Abstract]   [Full Text] [Related]  

  • 8. Major US consumer group asks FDA to ban drug for diabetes.
    Tanne JH
    BMJ; 2008 Nov; 337():a2401. PubMed ID: 18987042
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA approves nateglinide for treatment of type 2 diabetes.
    Lieder TR
    Am J Health Syst Pharm; 2001 Feb; 58(4):285, 288. PubMed ID: 11225164
    [No Abstract]   [Full Text] [Related]  

  • 10. A voyage of discovery.
    Gebel E
    Diabetes Forecast; 2013 Jun; 66(6):50-3. PubMed ID: 23802293
    [No Abstract]   [Full Text] [Related]  

  • 11. Rethinking the appraisal and approval of drugs for type 2 diabetes.
    Naci H; Lehman R; Wouters OJ; Goldacre B; Yudkin JS
    BMJ; 2015 Oct; 351():h5260. PubMed ID: 26452524
    [No Abstract]   [Full Text] [Related]  

  • 12. Novel diabetes drugs to face higher hurdles?
    Opar A
    Nat Rev Drug Discov; 2007 Sep; 6(9):687-9. PubMed ID: 17907340
    [No Abstract]   [Full Text] [Related]  

  • 13. Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes.
    Misbin RI
    Diabetes Care; 2007 Dec; 30(12):3141-4. PubMed ID: 18042753
    [No Abstract]   [Full Text] [Related]  

  • 14. New treatments for diabetes.
    Irony I; Parks MH; Meyer RJ
    N Engl J Med; 2007 May; 356(21):2221; author reply 2222-3. PubMed ID: 17526095
    [No Abstract]   [Full Text] [Related]  

  • 15. New treatments for diabetes.
    Raz I; Eldor R
    N Engl J Med; 2007 May; 356(21):2222; author reply 2222-3. PubMed ID: 17526096
    [No Abstract]   [Full Text] [Related]  

  • 16. Pancreatic safety of incretin-based drugs--FDA and EMA assessment.
    Egan AG; Blind E; Dunder K; de Graeff PA; Hummer BT; Bourcier T; Rosebraugh C
    N Engl J Med; 2014 Feb; 370(9):794-7. PubMed ID: 24571751
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapeutic use and adverse events of incretin-related drugs].
    Ishikawa M; Yamada Y
    Nihon Rinsho; 2012 May; 70 Suppl 3():699-702. PubMed ID: 22768601
    [No Abstract]   [Full Text] [Related]  

  • 18. Insulin secretagogues.
    Kock M
    J Assoc Physicians India; 1997; Suppl 1():48. PubMed ID: 11235637
    [No Abstract]   [Full Text] [Related]  

  • 19. Warner Lambert/Sankyo diabetes drug nears market.
    Nat Biotechnol; 1997 Feb; 15(2):113. PubMed ID: 9035120
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pharmacological and clinical profile of alogliptin benzoate (NESINA®)].
    Takeuchi K; Fujita T; Hiroi S
    Nihon Yakurigaku Zasshi; 2011 Jan; 137(1):43-50. PubMed ID: 21233588
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.